Fetal exposure to drugs may affect infants’ brain development

Translate to Spanish or other 102 languages!

New study demonstrates that in utero exposure to mother’s antiepileptic or antidepressant medication may affect development of the newborn brain networks. Image for illustration purposes
New study demonstrates that in utero exposure to mother’s antiepileptic or antidepressant medication may affect development of the newborn brain networks. Image for illustration purposes

Mega Doctor News

- Advertisement -

By University of Helsinki

Newswise — New study demonstrates that in utero exposure to mother’s antiepileptic or antidepressant medication may affect development of the newborn brain networks. In the study, novel mathematical methods were developed to allow future research on how commonly used drugs or other environmental conditions affect the newborn brain.

Pregnant mothers may need treatment for their medical conditions, such as mood disorder or epilepsy. The effects of such drug treatment on newborn brain network functions was examined in a study conducted at the BABA Center, a research unit in University of Helsinki and New Children’s Hospital of HUS Helsinki University Hospital. The study used electroencephalography (EEG) to measure electrical brain activity during sleep, and cortical network properties were calculated using advanced mathematical techniques.

- Advertisement -

“In prior studies, we have shown that changes in cortical activity across sleep states may provide important information on infants’ neurological condition,” Senior Researcher Anton Tokariev says.

The study demonstrated that exposure to antiepileptics and antidepressants during the fetal period leads to widespread changes in the cortical networks, and these effects may be specific to the type of drug exposure. In the case of antidepressants, the effect was more pronounced in local cortical networks. In contrast, exposure to antiepileptics had drug-specific effects on brain wide networks. Both drug types affected brain networks that are reactive to changes in sleep stages.

“What was clinically significant in the findings was that, some EEG findings linked to children’s subsequent neuropsychological development. Stronger changes in neural networks predicted a greater deviation in development at two years of age,” says Mari Videman, specialist in paediatric neurology at HUS Helsinki University Hospital.

Shedding new light on early brain development

- Advertisement -

The studies offer an entirely new way of assessing the effects of pharmaceutical agents on the development of child’s brain function.

“The EEG measurement technique developed at the BABA Center and its associated state-of-the-art mathematical assessment of the brain’s neural networks constitute breakthroughs in clinical research on early neurodevelopment,” Professor Sampsa Vanhatalo says.

Vanhatalo considers it particularly important that these EEG -based measures open a window into mechanisms that operate between neuronal cell. This leads to an opportunity to compare results observed in human children with research conducted using laboratory-animal models. Such translational work is needed to understand the mechanistic underpinnings of the drug effects. For instance, identical animal work is required to study how the amount or timing of maternal drug treatment would affect brain function of the offspring.

“Our novel methods provide a general analytical framework to support extensive future research on the questions how fetal brain development is affected by changes in intrauterine environment. Such studies may go far beyond maternal drug treatment, including also mother’s nutrition and overall physical condition, as well as myriad of further environmental factors,” Vanhatalo summarizes.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Texas Adds New Condition to Mandatory Newborn Screening Tests

The Texas Department of State Health Services added a new enzyme deficiency test on June 1, 2026, to its newborn screening panel, meaning that all Texas newborns are now tested for 60 rare, genetic conditions. Tests for hearing loss and critical congenital heart disease are additional point-of-service tests typically conducted by the birthing center. 

Pancreatic Cancer Patients Gain Early Access to Experimental Drug Daraxonrasib Following Fast-Track FDA Decision

The U.S. Food and Drug Administration is announcing that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol (EAP) for its experimental pancreatic cancer drug, daraxonrasib.

STHS GME Consortium Encourages Community to “Walk with a Doc”, June 6th

Mega Doctor News In an era defined by high-intensity workouts, wearable fitness trackers and advanced training techniques, one of simplest...

STHS Children’s Marks 20th Anniversary with Gala Honoring Pediatric Providers Behind Its Success

For the past 20 years, South Texas Health System Children’s has stood as a place where compassionate care and clinical excellence come together to create hope for children and their families.
- Advertisement -